Abstract Purpose of the Review The reintroduction of immune checkpoint inhibitors (ICIs)
after disease progression (rechallenge) or immune-related adverse events (irAEs) …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has made a
revolutionary difference in the treatment of malignant tumors, and considerably extended …

Background Immune checkpoint inhibition (ICI) has changed the melanoma treatment
spectrum. Few studies have examined the characteristics and long-term outcomes of …

Simple Summary In the era of immunotherapy, advanced melanoma patients have
unprecedentedly higher survival rates. However, the application of immunotherapy may lead …

Checkpoint inhibitor therapy for metastatic melanoma has dramatically improved outcomes.
Currently, 20 to 40% of treated patients achieve lengthy remissions. It is not clear whether …

With the increasing promise of long-term survival with immune checkpoint blockade (ICB)
therapies, particularly for patients with advanced melanoma, clinicians and investigators are …

Background Optimal duration of treatment (DoT) with immune checkpoint inhibitors (ICI) in
metastatic cancers remains unclear. Many patients, especially those without radiologic …

Traditional chemotherapy has been ineffective in the treatment of metastatic melanoma.
Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US …

Background: Immune checkpoint inhibition (ICI) has significantly improved the survival of
metastatic melanoma (MM) with a significant proportion of patients obtaining long-lasting …

Abstract Purpose of Review Emerging data indicate that immune checkpoint blockade (ICB)
in patients with metastatic melanoma can be stopped electively or at the time of toxicity with …